PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-27.92%
Both yoy net incomes decline, with CRVO at -222.91%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
3.10%
Some D&A expansion while CRVO is negative at -19.60%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-10.46%
Both cut yoy SBC, with CRVO at -100.00%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
292.72%
Well above CRVO's 554.86% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
215.28%
Lower AP growth vs. CRVO's 23020.65%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
292.72%
Growth well above CRVO's 35.84%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-67.58%
Negative yoy while CRVO is 0.00%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-21.90%
Negative yoy CFO while CRVO is 10.67%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-11.48%
Negative yoy CapEx while CRVO is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.48%
We reduce yoy invests while CRVO stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-59.52%
Negative yoy issuance while CRVO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.